Citations

Clear

7552 citation(s) found for "Ho, Matthew".

PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient
Sinnwell, Jason P. , Yu, Jia , Vedell, Peter T. , Weinshilboum, Richard M. , Wang, Liewei , Goetz, Matthew P. , Thompson, Kevin J. , Ingle, James N. , Suman, Vera, Sinnwell, Jason P , Kalari, Krishna R. , Tang, Xiaojia , Carlson, Erin E. , Weinshilboum, Richard M. , Boughey, Judy C. , Goetz, Matthew P. , Suman, Vera J.

Mayo Clinic

JCO Clinical Cancer Informatics | October 15, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-11

10.1200/cci.18.00012 | PMID 30652605 Get It

Purpose The majority of patients with cancer receive treatments that are minimally informed by omics data. We propose a precision medicine computational framework, PANOPLY (Precision Cancer Genomic Report: Single Sample Inventory), to identify and prioritize drug targets and cancer therapy regimens. Materials and Methods The PANOPLY approach integrates clinical data with germline and somatic features obtained from multiomics platforms and applies machine learning and network analysis approaches in the context of the individual patient and matched controls. The PANOPLY workflow uses the following four steps: selection of matched controls to the patient of interest; identification of patient-specific genomic events; identification of suitable drugs using the driver-gene network and random forest analyses; and provision of an integrated multiomics case report of the patient with prioritization of anticancer drugs. Results The PANOPLY workflow can be executed on a stand-alone virtual machine and is also available for download as an R package. We applied the method to an institutional breast cancer neoadjuvant chemotherapy study that collected clinical and genomic data as well as patient-derived xenografts to investigate the prioritization offered by PANOPLY. In a chemotherapy-resistant patient-derived xenograft model, we found that that the prioritized drug, olaparib, was more effective than placebo in treating the tumor ( P < .05). We also applied PANOPLY to in-house and publicly accessible multiomics tumor data sets with therapeutic response or survival data available. Conclusion PANOPLY shows promise as a means to prioritize drugs on the basis of clinical and multiomics data for an individual patient with cancer. Additional studies are needed to confirm this approach.
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Polster, Sean P. , Stadnik, Agnieszka , Akers, Amy , Christoforidis, Gregory A. , Fam, Maged D, Flemming, Kelly D. , Girard, Romuald , Hobson, Nicholas , Koskimäki, Janne , Lane, Karen , Liao, James K. , Lee, Cornelia , Lyne, Séan , McBee, Nichol , Piedad, Kristina , Sorrentino, Matthew J., Thompson, Richard E. , Whitehead, Kevin J. , Zeineddine, Hussein A. , Hanley, Daniel F. , Awad, Issam A. , Girard, Romuald , Hanley, Daniel F , Flemming, Kelly D , Cao, Ying , Hobson, Nicholas, Koenig, James I. , Morrison, Leslie , Shenkar, Robert , Polster, Sean P

Mayo Clinic

Neurosurgery | October 15, 2018 | Volume: 85 | Issue: 6 | Pages: 843-853

10.1093/neuros/nyy539 | PMID 30476251 Get It

Abstract BACKGROUND More than a million Americans harbor a cerebral cavernous angioma (CA), and those who suffer a prior symptomatic hemorrhage have an exceptionally high rebleeding risk. Preclinical studies show that atorvastatin blunts CA lesion development and hemorrhage through inhibiting RhoA kinase (ROCK), suggesting it may confer a therapeutic benefit. OBJECTIVE To evaluate whether atorvastatin produces a difference compared to placebo in lesional iron deposition as assessed by quantitative susceptibility mapping (QSM) on magnetic resonance imaging in CAs that have demonstrated a symptomatic hemorrhage in the prior year. Secondary aims shall assess effects on vascular permeability, ROCK activity in peripheral leukocytes, signal effects on clinical outcomes, adverse events, and prespecified subgroups. METHODS The phase I/IIa placebo-controlled, double-blinded, single-site clinical trial aims to enroll 80 subjects randomized 1-1 to atorvastatin (starting dose 80 mg PO daily) or placebo. Dosing shall continue for 24-mo or until reaching a safety endpoint. EXPECTED OUTCOMES The trial is powered to detect an absolute difference of 20% in the mean percent change in lesional QSM per year (2-tailed, power 0.9, alpha 0.05). A decrease in QSM change would be a signal of potential benefit, and an increase would signal a safety concern with the drug. DISCUSSION With firm mechanistic rationale, rigorous preclinical discoveries, and biomarker validations, the trial shall explore a proof of concept effect of a widely used repurposed drug in stabilizing CAs after a symptomatic hemorrhage. This will be the first clinical trial of a drug aimed at altering rebleeding in CA.
Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
Chu, Yaya, Shah, Tishi, Yin, Changhong , Barth, Matthew J. , Miles, Rodney R., Ayello, Janet, Morris, Erin , Harrison, Lauren , Ven, Carmella van de , Galardy, Paul J. , Goldman, Stanton, Lim, Megan S. , Hermiston, Michelle L. , McAllister‐Lucas, Linda M. , Giulino‐Roth, Lisa , Perkins, Sherrie L., Cairo, Mitchell S. , Galardy, Paul J , Lee, Sanghoon , Lim, Megan S

Mayo Clinic

OncoImmunology | October 11, 2018 | Volume: 8 | Issue: 1 | Pages: No page available

10.1080/2162402x.2018.1512455 | PMID 30546948 Get It

Above the GRADE: Evaluation of Guidelines in Critical Care Medicine*
Sims, Charles R. , Stelfox, Henry T. , Hyder, Joseph A. , Warner, Matthew A.

Mayo Clinic

Critical Care Medicine | October 9, 2018 | Volume: 47 | Issue: 1 | Pages: 109-113

10.1097/ccm.0000000000003467 | PMID 30303840 Get It

Objectives: We examined recommendations within critical care guidelines to describe the pairing patterns for strength of recommendation and quality of evidence. We further identified recommendations where the reported strength of recommendation was strong while the reported quality of evidence was not high/moderate and then assessed whether such pairings were within five paradigmatic situations offered by Grading of Recommendations Assessment, Development and Evaluation methodology to justify such pairings. Data Sources and Extraction: We identified all clinical critical care guidelines published online from 2011 to 2017 by the Society of Critical Care Medicine along with individual guidelines published by Surviving Sepsis Campaign, Kidney Disease Improving Global Outcomes, American Society for Parenteral and Enteral Nutrition, and the Infectious Disease Society of America/American Thoracic Society. Data Synthesis: In all, 15 documents specifying 681 eligible recommendations demonstrated variation in strength of recommendation (strong n = 215 [31.6%], weak n = 345 [50.7%], none n = 121 [17.8%]) and in quality of evidence (high n = 41 [6.0%], moderate n = 151 [22.2%], low/very low n = 298 [43.8%], and Expert Consensus/none n = 191 [28.1%]). Strength of recommendation and quality of evidence were positively correlated ( ρ = 0.66; p < 0.0001). Of 215 strong recommendations, 69 (32.1%) were discordantly paired with evidence other than high/moderate. Twenty-two of 69 (31.9%) involved Strong/Expert Consensus recommendations, a category discouraged by Grading of Recommendations Assessment, Development and Evaluation methodology. Forty-seven of 69 recommendations (68.1%) were comprised of Strong/Low or Strong/Very Low variation requiring justification within five paradigmatic scenarios. Among distribution in the five paradigmatic scenarios of Strong/Low and Strong/Very Low recommendations, the most common paradigmatic scenario was life threatening situation ( n = 20/47; 42.6%). Four Strong/Low or Strong/Very Low recommendations (4/47; 8.5%) were outside Grading of Recommendations Assessment, Development and Evaluation methodology. Conclusions: Among a large, diverse assembly of critical care guideline recommendations using Grading of Recommendations Assessment, Development and Evaluation methodology, the strength of evidence of a recommendation was generally associated with the quality of evidence. However, strong recommendations were not infrequently made in the absence of high/moderate quality of evidence. To improve clarity and uptake, future guideline statements may specify why such pairings were made, avoid such pairings when outside of Grading of Recommendations Assessment, Development and Evaluation criteria, and consider separate language for Expert Consensus recommendations (good practice statements).
Main Symptom that Led to Medical Evaluation and Diagnosis of Vestibular Schwannoma and Patient-Reported Tumor Size: Cross-sectional Study in 1,304 Patients
Peris‐Celda, Maria , Graffeo, Christopher S. , Perry, Avital , Kerezoudis, Panagiotis , Tombers, Nicole M. , Carlson, Matthew L. , Link, Michael J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | October 9, 2018 | Volume: 80 | Issue: 03 | Pages: 316-322

10.1055/s-0038-1675175 | PMID 31143577 Get It

Objectives Although vestibular schwannomas (VS) are known to cause cranial nerve deficits, cerebellar symptoms, and hydrocephalus, the role of these symptoms as the key driver of presentation from the patient's perspective has not been described. Our objective was to survey a large, retrospective VS cohort to document the patient-reported principal initial symptom, and self-reported tumor size, and to study trends in VS patient presentation. Methods Patients diagnosed with VS at our tertiary referral center and belonging to the Acoustic Neuroma Association (ANA) answered a questionnaire between 2015 and 2017. Demographic data, self-reported tumor size, and symptomatology were analyzed. Results 1,304 patients completed the questionnaire. Tumors were diagnosed from 1966 to 2017 at a mean 51.8 years (range: 8–86 years); 66% were female, and 1.1% had confirmed neurofibromatosis type 2 (NF2). Tumor size was reported using a 6-point scale: 0 to 1 cm (22.9%), 1 to 2 cm (28.7%), 2 to 3 cm (20.5%), 3 to 4 cm (10%), greater than 4 cm (7.2%), and unknown (10.6%). Hearing loss was the most common symptom that led to diagnosis (51.5%), followed by dizziness (17%), tinnitus (11.2%), and incidental diagnosis (10.2%); a fraction that has increased significantly in the last decade (p = 0.022). Larger tumors and NF2 were significantly associated with young age (p < 0.001). Conclusion Our large-scale questionnaire-driven review of 1,304 patients confirms that VS presentations are stereotypical, with most individuals recalling hearing loss, dizziness, or tinnitus as their chief complaint. Many tumors were incidentally diagnosed; an expanding population, attributable to increased access to magnetic resonance imaging (MRI). Large tumors were significantly more prevalent among younger patients at diagnosis, excluding NF2 patients, suggesting a more aggressive tumor biology that remains incompletely understood.
Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system
Walb, Matthew C., Carlson, Brett L. , Tryggestad, E., Tryggestad, Erik J, Sarkaria, Jann N.

Mayo Clinic

The British Journal of Radiology | October 9, 2018 | Volume: 92 | Issue: 1095 | Pages: 20180487

10.1259/bjr.20180487 | PMID 30299986 Get It

Abstract WP82: Screening Individuals With Intracranial Aneurysms for Abdominal Aortic Aneurysm - the Brain and Aortic Aneurysm Screening (BAAS) Study
Lescure, Tyler N , Rosenbaum, Blake L. , Rahman, Shareena , Green, Ilana E. , Berthaud, Jimmy V. , Barrett, Kevin M. , Worrall, Bradford B. , Carrera, Joseph , Thomas, Matthew , Southerland, Andrew M. , Meschia, James F.

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.wp82 Get It

Introduction: Aneurysm rupture is associated with high mortality and morbidity, including both intracranial aneurysms (IA) and abdominal aortic aneurysms (AAA). Despite potential preemptive treatment in those identified prior to IA or AAA rupture, the evidence for whom to screen remains limited. IA and AAA share both environmental and genetic risk, and prior cost-effectiveness models suggest the potential efficacy of screening in these high-risk individuals. We hypothesized that reciprocal screening in those presenting with IA for AAA would yield positive results. Methods: The BAAS study sought to establish the co-prevalence of IA and AAA. In this arm of BAAS, we recruited patients presenting with IA and screened them for AAA using abdominal ultrasound (aU/S) at two sites: Mayo Clinic and the University of Virginia (UVA). All participants underwent a detailed interview to collect demographic, radiographic, and clinical data. At UVA, participants also received genetic counseling. Results: At Mayo Clinic, we enrolled and screened 81 consecutive patients with aSAH (3 patients with known AAA were excluded) with 3 (3.7%) positive aU/S for AAA. At UVA, we recruited 195 consecutive patients presenting with ruptured or unruptured IA and completed screening aU/S in 178 (93%). Only one (0.6%) had an AAA. Conclusion: The lower positive screening at UVA (0.6%) which enrolled both ruptured and unruptured IA compared to the 3.7% positive results at Mayo suggests that future efforts to identify who with IA might benefit from AAA screening should focus on those with aneurysmal subarachnoid hemorrhage (aSAH).
Abstract TP82: Changes in the Distal Vessel Wall After Flow Diverter Treatment
Parameswaran, Praveen Kolumam, Ding, Yong Hong, Asnafi, Solmaz , Urban, Matthew M, Kallmes, David F. , Kadirvel, Ramanathan , Dai, Daying , Ding, Yonghong

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.tp82 Get It

Background: Flow diverters (FD) are increasingly used in the treatment of intracranial aneurysms. The risk of distal thromboembolic complications with FD is high, even in patients treated with dual antiplatelet therapy. The aim of the study was to understand the downstream vascular wall changes, by measuring the pulse wave velocity and vascular contractility following flow diverter treatment in a rabbit model. Methods: FD (Pipeline Embolic Device, Medtronic) were implanted in normal rabbits and sham-operated aorta were used as controls (n=5 for each group). Pulse wave imaging with ultra-fast ultrasound at 1600 frames per second (Vantage, Verasonics, Inc.) was performed in the vessel wall distal to FD, prior to device implantation and at 8 weeks follow up to measure the pulse wave propagation. Force contraction studies were conducted in the aortic rings using organ bath to assess the vascular functions. Results: The difference in pulse wave velocity (PWV) in the follow-up compared to pre-implantation was significantly higher (p=0.03,Fig 1A) in the distal vessels compared to sham controls (mean difference of PWV was 1.18 m/s and -0.37m/s, respectively as shown in Fig 1B). Conversely, the distal aortic segments to FD exhibited 55% increase in the level of vascular contractility compared to that of proximal segments (p=0.002). There is a significant positive correlation between mean PWV and mean vascular contractility. Conclusion: Our study found changes in the PWV after implantation of the FD, which correlated with vascular contractility. These results could explain vascular wall changes downstream following FD implantation.
Abstract 166: The Brain and Aortic Aneurysm Screening (BAAS) Study - Screening for Occult Intracranial Aneurysms in Those With Abdominal Aortic Aneurysms
Lescure, Tyler N , Rosenbaum, Blake L. , Rahman, Shareena , Green, Ilana E. , Berthaud, Jimmy V. , Barrett, Kevin M. , Worrall, Bradford B. , Carrera, Joseph , Thomas, Matthew , Meschia, James F. , Southerland, Andrew M.

Mayo Clinic

Stroke | October 8, 2018 | Volume: 49 | Issue: Suppl_1 | Pages: No page available

10.1161/str.49.suppl_1.166 Get It

Introduction: Abdominal aortic aneurysm (AAA) rupture has a mortality rate of 64% and intracranial aneurysm (IA) rupture has a mortality rate of 50%. Despite the high mortality rates, early detection and treatment of these vascular lesions prior to rupture can prevent devastating clinical outcomes, underscoring the need to identify high-risk populations for screening. Current evidence demonstrates shared genetic and environmental risk factors for both AAA and IA. Methods: The BAAS study sought to establish the co-prevalence of AAA and IA. In one arm of BAAS, we recruited patients presenting with AAA and screened them for IA. All participants underwent a detailed interview to collect demographic, radiographic, and clinical data and also had genetic counseling. Results: Of the 126 individuals with an AAA enrolled, 65% (82/126) completed the MRA. Difficulty with logistics of obtaining the research MRA with long distance travel to clinic was the principal reason for failure to obtain MRA. We identified 20.7% (17/82) with one or more IA, including 21 aneurysms found during systematic screening. IA ranged in size from 1.5-14 mm (height) x 1.4-7 mm (width) and varied in location. 9.5% (2/21) had a maximum diameter of 7 mm or more. One participant with a positive MRA underwent early coil embolization with the remainder undergoing continued clinical surveillance. Of the 15 individuals completing the genetic counseling screening, two underwent recommended clinical genetic testing, revealing one negative screen and one variant of unknown significance in the MYH11 gene. Conclusion: Consistent with our prior cost effectiveness models, these prospective data support the clinical utility of routine screening for IA in patients presenting with AAA.